Clinical trials: Lymphangioleiomyomatosis
Lung Disease, Pneumothorax
Study of the Disease Process of Lymphangioleiomyomatosis
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.
- Conditions
- Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis
- Trial name
- NCT00001465
- Testing
- Toshibia Aquilion One CT
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis (LAM)
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
The investigators will perform a two-center phase I trial of celecoxib (COX-2 inhibitor) administered at 200mg by mouth daily for 6 months. Up to 12 adult women with LAM will be recruited (between 4-8 at each site).
- Trial name
- COLA (NCT02484664)
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Perivascular Epithelioid Cell Tumor, Malignant
Molecular Characterization of Perivascular Epithelioid Cell Tumors
Perivascular epithelioid cell tumors (PEComas) are rare and are characterized by the expression of myomelanocytic markers. They are a complex family that includes angiomyolipomas, lymphangioleiomyomatoses and other soft tissue…
- Trial name
- PEComesCells (NCT05617105)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Lymphangioleiomyomatosis
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Background: Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air.
- Trial name
- NCT01799538
- Testing
- albuterol inhaler, albuterol nebulizer, PFT
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Respiratory Diseases, Cystic Fibrosis
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory…
- Conditions
- Chronic Respiratory Diseases, Cystic Fibrosis, Lymphangioleiomyomatosis, Hypersensitivity Pneumonitis
- Trial name
- NCT05727852
- Testing
- Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", Assessment of arterial stiffness using the VaSera VS-1500N
- Where
- Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Lymphangioleiomyomatosis
Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis (LAM) is a rare lung disease of women that is caused by genetic mutations. It results in the uncontrolled growth of an unusual type of smooth muscle cell in the lung.
- Trial name
- MILES (NCT00414648)
- Testing
- Sirolimus
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 89 people
- Sponsor
- University of Cincinnati
Hypomelanotic Macules, Facial Angiofibroma
Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)
International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s
- Conditions
- Hypomelanotic Macules, Facial Angiofibroma, Shagreen Patches, Ungual Fibromas
- Trial name
- TuScCom (NCT02654340)
- Where
- 8 sites in Albania, Egypt and 6 more
- Volunteers
- 20 people
- Sponsor
- CENTOGENE GmbH Rostock
Tuberous Sclerosis, Lymphangioleiomyomatosis
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.
- Trial name
- TESSTAL (NCT00490789)
- Testing
- sirolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cardiff University
Lymphangioleiomyomatosis
Discovery of Sirolimus Sensitive Biomarkers in Blood
Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive disease. It usually affects women in the prime of their lives. It typically results in lung destruction.
- Trial name
- NCT03304678
- Testing
- Sirolimus 2mg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis
LAM Pilot Study With Imatinib Mesylate
This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).
- Trial name
- LAMP-1 (NCT03131999)
- Testing
- Imatinib Mesylate 400Mg Capsule
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Lymphangioleiomyomatosis (LAM), Extracellular Vesicles; Generation and Function
Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex
Lymphangioleiomyomatosis (LAM) is a rare lung disease, linked to Tuberous Sclerosis Complex (TSC) or occurring sporadically, and involves abnormal mTORC1 activation.
- Trial name
- NCT07304856
- Testing
- Pulmonary Function Test, Analysis of Extracellular Vesicles
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Milan
Lymphangioleiomyomatosis, LAM
Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM)
Data from patients with the orphan disease of lymphangioleiomyomatosis (LAM) which performed a pulmonary Rehabilitation program will be analyzed retrospectively.
- Conditions
- Lymphangioleiomyomatosis, LAM, Pulmonary Rehabilitation
- Trial name
- NCT04184193
- Testing
- Pulmonary Rehabilitation
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Lymphangioleiomyomatosis, Sleep Disorder
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
Lymphangioleiomyomatosis (LAM) is a rare and progressive pulmonary disease of unknown etiology that almost exclusively affects women.
- Conditions
- Lymphangioleiomyomatosis, Sleep Disorder, Sleep Apnea Syndromes, Hypopnea Syndrome
- Trial name
- NCT04577937
- Testing
- LAM patients underwent PSG
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- dr. Stefano Nava
LAM, Lymphangioleiomyomatosis
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
- Trial name
- MILED (NCT03150914)
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati
Pulmonary Disease, Oropharyngeal Disease
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
This study will examine bacteria and toxins in the mouth, lung and digestive system that may be the cause of various diseases or symptoms. H.
- Conditions
- Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis
- Trial name
- NCT00366509
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis, Lymphangiomyomas
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM), a disease primarily of women of child-bearing age, is characterized by cystic lung disease and abdominal tumors (e.g., angiomyolipomas).
- Conditions
- Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
- Trial name
- NCT00005906
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Renal Angiomyolipoma
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
- Trial name
- NCT03525834
- Testing
- Everolimus
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Lymphangioleiomyomatosis
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Lymphangioleiomyomatosis (LAM) is a rare lung disease that mostly affects women of childbearing age. In LAM, abnormal, muscle-like cells begin to grow out of control in the lungs.
- Trial name
- NCT02116712
- Testing
- Saracatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Tony Eissa
Lymphangioleiomyomatosis
National Lymphangioleiomyomatosis Registry, France
RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the…
- Trial name
- RE-LAM-CE (NCT01484236)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Vincent COTTIN